Literature DB >> 4916539

Immunosuppressive therapy for the eye changes of Graves' disease.

G N Burrow, M S Mitchell, R O Howard, L B Morrow.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4916539     DOI: 10.1210/jcem-31-3-307

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  9 in total

Review 1.  Immunosuppressant therapy of thyroid eye disease.

Authors:  G Kahaly; J Beyer
Journal:  Klin Wochenschr       Date:  1988-11-01

2.  Progress in endocrine exophthalmos.

Authors:  C W Havard
Journal:  Br Med J       Date:  1979-04-14

3.  Thyrotoxicosis developing during cyclophosphamide therapy.

Authors:  I R McDougall; W R Greig; H W Gray; J F Smith
Journal:  Br Med J       Date:  1971-10-30

Review 4.  Ocular manifestations of Graves' disease: a review.

Authors:  A P Weetman; A M McGregor; R Hall
Journal:  J R Soc Med       Date:  1984-11       Impact factor: 5.344

5.  Squamous cell carcinoma of the eyelid masquerading as 'malignant' ophthalmopathy of Graves's disease.

Authors:  H C Ford; J W Delahunt; C A Teague
Journal:  Br J Ophthalmol       Date:  1983-09       Impact factor: 4.638

6.  The ophthalmopathy of Graves' disease.

Authors:  D Rapoport
Journal:  West J Med       Date:  1985-04

7.  Dysthyroid ophthalmopathy: an update.

Authors:  L A Young
Journal:  J Natl Med Assoc       Date:  1979-09       Impact factor: 1.798

8.  Clinical use of immunosuppressive drugs: part II.

Authors:  N L Gerber; A D Steinberg
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 9.  Graves' ophthalmopathy.

Authors:  J R Wall; J Henderson; C R Strakosch; D M Joyner
Journal:  Can Med Assoc J       Date:  1981-04-01       Impact factor: 8.262

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.